Contact
searchSearch
HMP Global
Login

Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma
Specialty Channel
News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
Quiz
High-Risk Stratification in Cutaneous Squamous Cell Carcinoma
02/19/2026
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results...
02/19/2026
Oncology
News
High-Risk Features Predict Inferior Survival in Cutaneous Squamous Cell Carcinoma of the Head and Neck
02/04/2026
Stephanie Holland
Results from a secondary analysis of the phase 3 TROG 05.01 trial identified a subgroup of patients with high-risk cutaneous squamous cell carcinoma of the head and neck who experienced significantly worse survival following postoperative...
Results from a secondary analysis of the phase 3 TROG 05.01 trial identified a subgroup of patients with high-risk cutaneous squamous cell carcinoma of the head and neck who experienced significantly worse survival following postoperative...
Results from a secondary...
02/04/2026
Oncology
Quiz
Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
02/04/2026
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA...
02/04/2026
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Increase
01/29/2026
Stephanie Holland
Results from a nationwide, population-based study demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ increased steadily over nearly two decades, highlighting the growing burden...
Results from a nationwide, population-based study demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ increased steadily over nearly two decades, highlighting the growing burden...
Results from a nationwide,...
01/29/2026
Oncology
FDA Approval
FDA Approves Cemiplimab for Patients With Cutaneous Squamous Cell Carcinoma in the Adjuvant Setting
10/08/2025
Allison Casey
The US FDA approved cemiplimab for the adjuvant treatment of patients with cutaneous squamous cell carcinoma who are at high risk for recurrence following surgery and radiation.
The US FDA approved cemiplimab for the adjuvant treatment of patients with cutaneous squamous cell carcinoma who are at high risk for recurrence following surgery and radiation.
The US FDA approved cemiplimab...
10/08/2025
Oncology
News
Using Risk Factors for Metastasis to Improve Cutaneous Squamous Cell Carcinoma Staging Systems
08/09/2022
Derek Cowsert
Retrospective study aims to identify variables for significant risk of metastasis in patients with cutaneous squamous cell carcinoma.
Retrospective study aims to identify variables for significant risk of metastasis in patients with cutaneous squamous cell carcinoma.
Retrospective study aims to...
08/09/2022
Oncology

News

News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
News
High-Risk Features Predict Inferior Survival in Cutaneous Squamous Cell Carcinoma of the Head and Neck
02/04/2026
Stephanie Holland
Results from a secondary analysis of the phase 3 TROG 05.01 trial identified a subgroup of patients with high-risk cutaneous squamous cell carcinoma of the head and neck who experienced significantly worse survival following postoperative...
Results from a secondary analysis of the phase 3 TROG 05.01 trial identified a subgroup of patients with high-risk cutaneous squamous cell carcinoma of the head and neck who experienced significantly worse survival following postoperative...
Results from a secondary...
02/04/2026
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Increase
01/29/2026
Stephanie Holland
Results from a nationwide, population-based study demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ increased steadily over nearly two decades, highlighting the growing burden...
Results from a nationwide, population-based study demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ increased steadily over nearly two decades, highlighting the growing burden...
Results from a nationwide,...
01/29/2026
Oncology
News
Using Risk Factors for Metastasis to Improve Cutaneous Squamous Cell Carcinoma Staging Systems
08/09/2022
Derek Cowsert
Retrospective study aims to identify variables for significant risk of metastasis in patients with cutaneous squamous cell carcinoma.
Retrospective study aims to identify variables for significant risk of metastasis in patients with cutaneous squamous cell carcinoma.
Retrospective study aims to...
08/09/2022
Oncology

Interactive Features

Quiz
High-Risk Stratification in Cutaneous Squamous Cell Carcinoma
02/19/2026
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results...
02/19/2026
Oncology
Quiz
Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
02/04/2026
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA...
02/04/2026
Oncology

Recent News

News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
News
High-Risk Features Predict Inferior Survival in Cutaneous Squamous Cell Carcinoma of the Head and Neck
02/04/2026
Stephanie Holland
Results from a secondary analysis of the phase 3 TROG 05.01 trial identified a subgroup of patients with high-risk cutaneous squamous cell carcinoma of the head and neck who experienced significantly worse survival following postoperative...
Results from a secondary analysis of the phase 3 TROG 05.01 trial identified a subgroup of patients with high-risk cutaneous squamous cell carcinoma of the head and neck who experienced significantly worse survival following postoperative...
Results from a secondary...
02/04/2026
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Increase
01/29/2026
Stephanie Holland
Results from a nationwide, population-based study demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ increased steadily over nearly two decades, highlighting the growing burden...
Results from a nationwide, population-based study demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ increased steadily over nearly two decades, highlighting the growing burden...
Results from a nationwide,...
01/29/2026
Oncology
News
Using Risk Factors for Metastasis to Improve Cutaneous Squamous Cell Carcinoma Staging Systems
08/09/2022
Derek Cowsert
Retrospective study aims to identify variables for significant risk of metastasis in patients with cutaneous squamous cell carcinoma.
Retrospective study aims to identify variables for significant risk of metastasis in patients with cutaneous squamous cell carcinoma.
Retrospective study aims to...
08/09/2022
Oncology
FDA Approval
FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases
08/04/2026
Stephanie Holland
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab...
08/04/2026
Oncology
FDA Alerts
FDA Advisory Committee Backs RP1 Plus Nivolumab for Advanced Melanoma in 10-3 Vote
07/31/2026
Stephanie Holland
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and...
07/31/2026
Oncology
FDA Alerts
Subcutaneous Amivantamab Receives FDA Priority Review for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/30/2026
Emily Estrada
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review...
07/30/2026
Oncology
News
Regorafenib Producess High Response and Durable Disease Control in KIT-Mutant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial...
07/29/2026
Oncology
News
Ceralasertib Plus Durvalumab Demonstrates Limited Activity in PD-L1-Resistant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found...
07/29/2026
Oncology
News
Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors
07/28/2026
Emily Estrada
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that...
07/28/2026
Oncology
News
Real-World Study Highlights Evolving Treatment Patterns and Petsistent Diagnostic Challenges in Patients With Desmoid Tumors
07/28/2026
Emily Estrada
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated...
07/28/2026
Oncology
News
Real-World Analysis Identifies Performance Status as a Key Predictor of Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/28/2026
Stephanie Holland
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest...
07/28/2026
Oncology
News
Izalontamab Brengitecan Shows Promising Clinical Activity in Previously Treated Extensive-Stage Small Cell Lung Cancer
07/28/2026
Stephanie Holland
Results from a phase 1b dose-expansion study demonstrated that izalontamab brengitecan, a bispecific antibody-drug conjugate targeting EGFR and HER3, produced encouraging antitumor activity in patients with relapsed extensive-stage small cell...
Results from a phase 1b dose-expansion study demonstrated that izalontamab brengitecan, a bispecific antibody-drug conjugate targeting EGFR and HER3, produced encouraging antitumor activity in patients with relapsed extensive-stage small cell...
Results from a phase 1b...
07/28/2026
Oncology
News
Advanced Age Does Not Compromise Azacitidine Outcomes in Higher-Risk Myelodysplastic Syndromes
07/27/2026
Emily Estrada
Results from a retrospective, real-world study demonstrated that azacitidine produced comparable efficacy and tolerability in elderly and younger patients with higher-risk myelodysplastic syndromes, supporting its continued use as first-line...
Results from a retrospective, real-world study demonstrated that azacitidine produced comparable efficacy and tolerability in elderly and younger patients with higher-risk myelodysplastic syndromes, supporting its continued use as first-line...
Results from a retrospective,...
07/27/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use